These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33468901)

  • 1. [Clinical Practice of the Efficiency and Safety of Palbociclib in Patients with Metastatic Breast Cancer].
    Morikawa N; Yoshitomi S; Hara K; Mimata A; Tsuji H
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2183-2185. PubMed ID: 33468901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
    Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
    Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
    Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
    Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer].
    Iwamoto N; Aruga T; Miyamoto H; Saita C; Onishi M; Goto R; Ishiba T; Honda Y; Kuroi K
    Gan To Kagaku Ryoho; 2019 Jul; 46(7):1137-1140. PubMed ID: 31296819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
    Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
    Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single institution experience with palbociclib toxicity requiring dose modifications.
    Gong J; Cho M; Yu KW; Waisman J; Yuan Y; Mortimer J
    Breast Cancer Res Treat; 2018 Apr; 168(2):381-387. PubMed ID: 29218462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
    Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib and Letrozole in Advanced Breast Cancer.
    Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
    N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
    Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
    Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
    Seki H; Sakurai T; Maeda Y; Oki N; Aoyama M; Yamaguchi R; Tokuda T; Kaburagi T; Okumura T; Karahashi T; Nakajima K; Higeta K; Shimizu K
    In Vivo; 2019; 33(6):2037-2044. PubMed ID: 31662535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
    Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
    Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
    Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
    Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
    Finn RS; Rugo HS; Gelmon KA; Cristofanilli M; Colleoni M; Loi S; Schnell P; Lu DR; Theall KP; Mori A; Gauthier E; Bananis E; Turner NC; Diéras V
    Oncologist; 2021 May; 26(5):e749-e755. PubMed ID: 33486783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
    Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.